No CrossRef data available.
Article contents
Prolactin levels and agressive behaviour in men with Schizophrenia
Published online by Cambridge University Press: 19 July 2023
Abstract
Recent studies find a high level of prolactin in naive patients with consequences on their behavior. These results have shed light on new etiopathogenic avenues in schizophrenia and suggested new preventive approaches.
The objective of our work was to investigate the links that may involve prolactin levels to agressive behavior in patients followed for antipsychotic-naïve schizophrenia or in therapeutic discontinuation.
We conducted a one-year descriptive and cross-sectional study of thirty male patients hospitalized for a treatment-naïve psychotic relapse or who had been discontinued for more than two months. These patients were assessed using a questionnaire as well as the Overt Agression Scale (OAS). A blood sample was taken to specify the prolactin level.
Eleven patients were aggressive (37%). Seven patients (23%) had hyperprolactinemia. Hyperprolactinemia was also inversely associated with aggression since inversely significant correlations were objectified for prolactinemia and respectively the OAS score and the verbal aggression subscore (Rho=-0.391 ; p=0.033) and (p=0.016, Rho=-0.438). The score of aggressiveness towards others also evolved inversely to the prolactin level with a p close to significance (p =0.056).
Our results support the hypothesis of a probable action of prolactin as a protective factor against aggression. High prolactin levels may therefore represent a diagnostic lead for a particular profile of a certain patient group with a particular course. However, this subject is still unresolved in the literature and future studies seem necessary.
None Declared
- Type
- Abstract
- Information
- European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S440
- Creative Commons
- This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Copyright
- © The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Comments
No Comments have been published for this article.